Study shows efficacy of Resolute Integrity drug-eluting stent in coronary artery disease- Medtronic

Researchers have presented data from the independent BIO-RESORT study comparing the safety and efficacy of biodegradable polymer stents to Resolute Integrity drug-eluting stent from Medtronic in patients with coronary artery disease. At one year, patients with coronary artery disease who were treated with a biodegradable polymer stent showed no clinical benefits over patients treated with Resolute Integrity. Neither of these biodegradable stents have been compared with the new-generation thin-strut Resolute Integrity zotarolimus-eluting stent which is an established device.

In the BIO-RESORT study, the primary composite endpoint of target vessel failure at one-year showed no statistically significant difference in outcomes for the Resolute Integrity treated group(N=1173) at 5.4 percent compared to 4.7 percent with the Synergy biodegradable polymer stent (BP-DES) arm and 4.7 percent with the Orsiro BP-DES am (difference of 0.7 percent; p =0.45 for Synergy and p =0.46 for Orsiro). The one year outcomes also found no statistically significant difference in stent thrombosis between Resolute Integrity and the BP-DES groups (difference of 0.1 percent; p =0.77). The results were presented at the Transcatheter Cardiovascular Therapeutics Annual Meeting and simultaneously published in The Lancet.

See: "Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial" Clemens von Birgelen et al. The Lancet online 30 October 2016 DOI: http://dx.doi.org/10.1016/S0140-6736(16)31920-1